# Levosimendan Administration in Pulmonary Hypertension

> **NCT04599816** · NA · COMPLETED · sponsor: **Aretaieion University Hospital** · enrollment: 45 (actual)

## Conditions studied

- Hypertension, Pulmonary
- Cardiac Failure
- Pulmonary Vascular Resistance Abnormality

## Interventions

- **DRUG:** levosimendan at a dose of 3 mcg/kg
- **DRUG:** levosimendan at a dose of 6 mcg/kg
- **DRUG:** levosimendan at a dose of 12 mcg/kg

## Key facts

- **NCT ID:** NCT04599816
- **Lead sponsor:** Aretaieion University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-17
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-10-17
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599816, "Levosimendan Administration in Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04599816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*